TISSIUM Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
128
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
15
TISSIUM General Information
Description
Developer of biodegradable programmable polymer technology designed for tissue reconstruction and adaptable for use in multiple clinical areas. The company's technology uses biomorphic reconstructive polymers for biodegradable sealants and adhesives for surgical-wound closure that are non-toxic, designed to bind strongly to tissues and deliver immediate wound closure within the dynamic environments of the body, enabling surgeons to treat patients with a polymer that can be used in the fields of tissue repair and localized drug delivery.
Contact Information
Website
www.tissium.comCorporate Office
- 74 rue du Faubourg Saint-Antoine
- 75012 Paris
- France
Corporate Office
- 74 rue du Faubourg Saint-Antoine
- 75012 Paris
- France
TISSIUM Timeline
TISSIUM Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Accelerator/Incubator | 05-Jun-2025 | Completed | Generating Revenue | |||
| 10. Grant | 15-Jun-2023 | Completed | Generating Revenue | |||
| 9. Later Stage VC (Series D) | 23-May-2023 | Completed | Generating Revenue | |||
| 8. Accelerator/Incubator | 01-Feb-2022 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series C) | 31-Aug-2021 | Completed | Generating Revenue | |||
| 6. Debt - General | 01-Oct-2020 | Completed | Pre-Clinical Trials | |||
| 5. Later Stage VC (Series B) | 20-Nov-2019 | Completed | Pre-Clinical Trials | |||
| 4. Grant | 24-Jan-2018 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC (Series A2) | 30-Jul-2017 | $25.9M | $36.4M | Completed | Pre-Clinical Trials | |
| 2. Debt - General | 30-Jun-2016 | $1.57M | $10.5M | Completed | Pre-Clinical Trials |
TISSIUM Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| D Shares | ||||||||
| C Shares | ||||||||
| B Shares | ||||||||
| A2 Shares | 499,998 | $0.010972 | $49.37 | $49.37 | 1x | $49.37 | 2.08% | |
| A Shares | 210,526 | $0.010972 | $41.69 | $41.69 | 1x | $41.69 | 0.88% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
TISSIUM Comparisons
Industry
Financing
Details
TISSIUM Competitors (9)
One of TISSIUM’s 9 competitors is NorthStar Medical Radioisotopes, a Venture Capital-Backed company based in Beloit, WI.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NorthStar Medical Radioisotopes | Venture Capital-Backed | Beloit, WI | ||||
| Cardiac Dimensions | Venture Capital-Backed | Kirkland, WA | ||||
| TELA Bio | Formerly VC-backed | Malvern, PA | ||||
| ViewRay | Formerly VC-backed | Bedford, OH | ||||
| Baxter International (Medical Equipment) | Corporation | Deerfield, IL |
TISSIUM Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
TISSIUM Patents
TISSIUM Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4450074-A1 | Composition for use in tissue reconstruction and tissue regrowth | Pending | 18-Apr-2023 | ||
| AU-2023414196-A1 | Nerve conduit system | Pending | 27-Dec-2022 | ||
| CA-223063-S | Device cap for medical use for applying an adhesive composition for surgical use | Active | 23-Nov-2022 | ||
| CA-223200-S | Device for medical use for applying an adhesive composition for surgical use | Active | 23-Nov-2022 | ||
| US-D1031978-S1 | Medical device | Active | 23-Nov-2022 |
TISSIUM Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
TISSIUM Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ISALT- Strategic Long Term Equity Investments | PE/Buyout | Minority | ||
| Mérieux Equity Partners | PE/Buyout | Minority | ||
| La French Tech | Accelerator/Incubator | |||
| Cathay Capital Private Equity | PE/Buyout | Minority | ||
| Cathay Health | Venture Capital | Minority |
TISSIUM FAQs
-
When was TISSIUM founded?
TISSIUM was founded in 2013.
-
Where is TISSIUM headquartered?
TISSIUM is headquartered in Paris, France.
-
What is the size of TISSIUM?
TISSIUM has 128 total employees.
-
What industry is TISSIUM in?
TISSIUM’s primary industry is Other Devices and Supplies.
-
Is TISSIUM a private or public company?
TISSIUM is a Private company.
-
What is TISSIUM’s current revenue?
The current revenue for TISSIUM is .
-
How much funding has TISSIUM raised over time?
TISSIUM has raised $201M.
-
Who are TISSIUM’s investors?
ISALT- Strategic Long Term Equity Investments, Mérieux Equity Partners, La French Tech, Cathay Capital Private Equity, and Cathay Health are 5 of 15 investors who have invested in TISSIUM.
-
Who are TISSIUM’s competitors?
NorthStar Medical Radioisotopes, Cardiac Dimensions, TELA Bio, ViewRay, and Baxter International (Medical Equipment) are some of the 9 competitors of TISSIUM.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
